5 takeaways from Becton Dickinson’s $24B acquisition of C.R. Bard (Updated)
One reason for the deal is Bard will help expand BD’s focus on the treatment of disease states beyond diabetes.
One reason for the deal is Bard will help expand BD’s focus on the treatment of disease states beyond diabetes.